Xenograft Model Antitumor Assays

"Xenograft Model Antitumor Assays" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.

Descriptor ID	D023041
MeSH Number(s)	E05.337.550.200.900 E05.624.850
Concept/Terms	Xenograft Model Antitumor Assays Xenograft Model Antitumor Assays Tumor Xenograft Assay Xenograft Antitumor Assays Antitumor Assay, Xenograft Antitumor Assays, Xenograft Assay, Xenograft Antitumor Assays, Xenograft Antitumor Xenograft Antitumor Assay Antitumor Assays, Xenograft Model

Below are MeSH descriptors whose meaning is more general than "Xenograft Model Antitumor Assays".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Investigative Techniques [E05]
Evaluation Studies as Topic [E05.337]
Drug Evaluation, Preclinical [E05.337.550]
Drug Screening Assays, Antitumor [E05.337.550.200]
Xenograft Model Antitumor Assays [E05.337.550.200.900]
Neoplasm Transplantation [E05.624]
Xenograft Model Antitumor Assays [E05.624.850]

Below are MeSH descriptors whose meaning is related to "Xenograft Model Antitumor Assays".

Below are MeSH descriptors whose meaning is more specific than "Xenograft Model Antitumor Assays".

Xenograft Model Antitumor Assays
Subrenal Capsule Assay

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Xenograft Model Antitumor Assays" by people in this website by year, and whether "Xenograft Model Antitumor Assays" was a major or minor topic of these publications.

Bar chart showing 145 publications over 18 distinct years, with a maximum of 17 publications in 2011

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2002	1	2	3
2003	0	1	1
2004	0	2	2
2005	0	4	4
2006	0	5	5
2007	0	3	3
2008	0	10	10
2009	1	8	9
2010	1	13	14
2011	1	16	17
2012	1	12	13
2013	0	10	10
2014	0	10	10
2015	1	12	13
2016	2	7	9
2017	0	7	7
2018	0	5	5
2019	1	9	10

Below are the most recent publications written about "Xenograft Model Antitumor Assays" by people in Profiles.

Raghubir M, Rahman CN, Fang J, Matsui H, Mahajan SS. Osteosarcoma growth suppression by riluzole delivery via iron oxide nanocage in nude mice. Oncol Rep. 2020 Jan; 43(1):169-176.

View in: PubMed
Kaoud TS, Johnson WH, Ebelt ND, Piserchio A, Zamora-Olivares D, Van Ravenstein SX, Pridgen JR, Edupuganti R, Sammons R, Cano M, Warthaka M, Harger M, Tavares CDJ, Park J, Radwan MF, Ren P, Anslyn EV, Tsai KY, Ghose R, Dalby KN. Modulating multi-functional ERK complexes by covalent targeting of a recruitment site in vivo. Nat Commun. 2019 11 19; 10(1):5232.

View in: PubMed
Goren L, Zhang G, Kaushik S, Breslin PAS, Du YN, Foster DA. (-)-Oleocanthal and (-)-oleocanthal-rich olive oils induce lysosomal membrane permeabilization in cancer cells. PLoS One. 2019; 14(8):e0216024.

View in: PubMed
Elie BT, Hubbard K, Pechenyy Y, Layek B, Prabha S, Contel M. Preclinical evaluation of an unconventional ruthenium-gold-based chemotherapeutic: RANCE-1, in clear cell renal cell carcinoma. Cancer Med. 2019 08; 8(9):4304-4314.

View in: PubMed
Young LA, O'Connor LO, de Renty C, Veldman-Jones MH, Dorval T, Wilson Z, Jones DR, Lawson D, Odedra R, Maya-Mendoza A, Reimer C, Bartek J, Lau A, O'Connor MJ. Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress. Cancer Res. 2019 07 15; 79(14):3762-3775.

View in: PubMed
Xu C, Ooi WF, Qamra A, Tan J, Chua BY, Ho SWT, Das K, Adam Isa ZF, Li Z, Yao X, Yan T, Xing M, Huang KK, Lin JS, Nandi T, Tay ST, Lee MH, Tan ALK, Ong X, Ashktorab H, Smoot D, Li S, Ng SC, Teh BT, Tan P. HNF4a pathway mapping identifies wild-type IDH1 as a targetable metabolic node in gastric cancer. Gut. 2020 02; 69(2):231-242.

View in: PubMed
Zhu Q, Ding L, Zi Z, Gao S, Wang C, Wang Y, Zhu C, Yuan Z, Wei F, Cai Q. Viral-Mediated AURKB Cleavage Promotes Cell Segregation and Tumorigenesis. Cell Rep. 2019 03 26; 26(13):3657-3671.e5.

View in: PubMed
Ma J, Benitez JA, Li J, Miki S, Ponte de Albuquerque C, Galatro T, Orellana L, Zanca C, Reed R, Boyer A, Koga T, Varki NM, Fenton TR, Nagahashi Marie SK, Lindahl E, Gahman TC, Shiau AK, Zhou H, DeGroot J, Sulman EP, Cavenee WK, Kolodner RD, Chen CC, Furnari FB. Inhibition of Nuclear PTEN Tyrosine Phosphorylation Enhances Glioma Radiation Sensitivity through Attenuated DNA Repair. Cancer Cell. 2019 03 18; 35(3):504-518.e7.

View in: PubMed
Wei F, Zhang T, Deng SC, Wei JC, Yang P, Wang Q, Chen ZP, Li WL, Chen HC, Hu H, Cao J. PD-L1 promotes colorectal cancer stem cell expansion by activating HMGA1-dependent signaling pathways. Cancer Lett. 2019 05 28; 450:1-13.

View in: PubMed
Gao C, Xiao G, Piersigilli A, Gou J, Ogunwobi O, Bargonetti J. Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells. Breast Cancer Res. 2019 01 14; 21(1):5.

View in: PubMed

People

Explore

Similar Concepts

Top Journals